Teva Pharmaceutical Industries Sees Unusually High Options Volume (NYSE:TEVA)

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) was the recipient of unusually large options trading on Tuesday. Traders bought 16,778 call options on the company. This represents an increase of approximately 51% compared to the typical volume of 11,088 call options.

Analyst Ratings Changes

Several brokerages have commented on TEVA. Bank of America upped their price target on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, April 9th. Piper Sandler restated an “overweight” rating and set a $42.00 price objective (up from $41.00) on shares of Teva Pharmaceutical Industries in a research note on Thursday, April 30th. Truist Financial raised their target price on Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the company a “buy” rating in a report on Thursday, April 30th. Barclays upped their price target on Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the stock an “overweight” rating in a report on Wednesday, May 6th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company an “overweight” rating in a research report on Thursday, April 30th. Nine research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $41.78.

Insiders Place Their Bets

In related news, CAO Amir Weiss sold 10,679 shares of the company’s stock in a transaction on Wednesday, May 6th. The stock was sold at an average price of $36.00, for a total value of $384,444.00. Following the completion of the transaction, the chief accounting officer directly owned 20,016 shares in the company, valued at approximately $720,576. This represents a 34.79% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Christine Fox sold 21,258 shares of Teva Pharmaceutical Industries stock in a transaction dated Thursday, April 30th. The shares were sold at an average price of $35.31, for a total value of $750,619.98. Following the completion of the sale, the executive vice president owned 63,647 shares of the company’s stock, valued at $2,247,375.57. This trade represents a 25.04% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 465,931 shares of company stock valued at $16,332,989. 0.54% of the stock is currently owned by company insiders.

Institutional Trading of Teva Pharmaceutical Industries

A number of large investors have recently modified their holdings of the company. AQR Capital Management LLC boosted its stake in Teva Pharmaceutical Industries by 24.6% during the 1st quarter. AQR Capital Management LLC now owns 23,955 shares of the company’s stock valued at $368,000 after purchasing an additional 4,732 shares during the period. Focus Partners Wealth grew its holdings in Teva Pharmaceutical Industries by 4.5% in the 1st quarter. Focus Partners Wealth now owns 40,074 shares of the company’s stock worth $616,000 after buying an additional 1,739 shares in the last quarter. Franklin Resources Inc. acquired a new stake in Teva Pharmaceutical Industries in the 2nd quarter valued at approximately $255,000. Flow Traders U.S. LLC bought a new stake in Teva Pharmaceutical Industries during the 2nd quarter valued at $238,000. Finally, Cerity Partners LLC boosted its position in Teva Pharmaceutical Industries by 2.9% during the 2nd quarter. Cerity Partners LLC now owns 45,837 shares of the company’s stock worth $768,000 after acquiring an additional 1,291 shares during the period. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Up 2.0%

TEVA traded up $0.64 on Tuesday, reaching $32.84. The company’s stock had a trading volume of 2,337,565 shares, compared to its average volume of 7,676,710. Teva Pharmaceutical Industries has a 1 year low of $14.99 and a 1 year high of $37.35. The business’s 50 day moving average is $33.55 and its 200 day moving average is $32.27. The company has a debt-to-equity ratio of 1.70, a current ratio of 1.01 and a quick ratio of 0.78. The stock has a market cap of $37.76 billion, a price-to-earnings ratio of 24.69, a price-to-earnings-growth ratio of 3.29 and a beta of 0.84.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Tuesday, March 31st. The company reported $0.53 EPS for the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%.The company had revenue of $3.98 billion during the quarter. As a group, research analysts forecast that Teva Pharmaceutical Industries will post 2.31 EPS for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.